miRNA
Mirxes Gets $40M Financing From CBC Group's R-Bridge to Support Global Expansion
The company is developing blood-based microRNA tests for early cancer detection and screening, with its flagship assay, GastroClear, already approved as an IVD in Singapore.
The company hopes to attract investors to fund its next steps after publishing early data from a training and validation study using public miRNA data.
MicroRNA Discoverers Win Nobel Prize in Physiology or Medicine
Victor Ambros and Gary Ruvkun were awarded the prize for identifying the small noncoding RNAs and their role in gene regulation.
The nonprofit behind the work aims to bring the test to market in the next 18 to 24 months and is in discussions with potential commercialization partners.
Mirxes, Universiti Kebangsaan Malaysia Partner on Colorectal Cancer Detection Test
The partners aim to develop a blood-based colorectal cancer test for the Malaysian market using Mirxes' proprietary microRNA technology.
Aug 5, 2021
Jul 30, 2021
Nov 4, 2020
Oct 22, 2020